KR20250065424A - 항-cd73 항체 및 이의 용도 - Google Patents
항-cd73 항체 및 이의 용도 Download PDFInfo
- Publication number
- KR20250065424A KR20250065424A KR1020257013451A KR20257013451A KR20250065424A KR 20250065424 A KR20250065424 A KR 20250065424A KR 1020257013451 A KR1020257013451 A KR 1020257013451A KR 20257013451 A KR20257013451 A KR 20257013451A KR 20250065424 A KR20250065424 A KR 20250065424A
- Authority
- KR
- South Korea
- Prior art keywords
- ser
- seq
- tyr
- gly
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Fats And Perfumes (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862640955P | 2018-03-09 | 2018-03-09 | |
| US62/640,955 | 2018-03-09 | ||
| US201862721044P | 2018-08-22 | 2018-08-22 | |
| US62/721,044 | 2018-08-22 | ||
| US201862786598P | 2018-12-31 | 2018-12-31 | |
| US62/786,598 | 2018-12-31 | ||
| KR1020207027633A KR102804816B1 (ko) | 2018-03-09 | 2019-03-05 | 항-cd73 항체 및 이의 용도 |
| PCT/US2019/020688 WO2019173291A1 (en) | 2018-03-09 | 2019-03-05 | Anti-cd73 antibodies and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207027633A Division KR102804816B1 (ko) | 2018-03-09 | 2019-03-05 | 항-cd73 항체 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250065424A true KR20250065424A (ko) | 2025-05-12 |
Family
ID=67846304
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257013451A Pending KR20250065424A (ko) | 2018-03-09 | 2019-03-05 | 항-cd73 항체 및 이의 용도 |
| KR1020207027633A Active KR102804816B1 (ko) | 2018-03-09 | 2019-03-05 | 항-cd73 항체 및 이의 용도 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207027633A Active KR102804816B1 (ko) | 2018-03-09 | 2019-03-05 | 항-cd73 항체 및 이의 용도 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11299550B2 (enExample) |
| EP (1) | EP3762030A4 (enExample) |
| JP (2) | JP7334177B2 (enExample) |
| KR (2) | KR20250065424A (enExample) |
| CN (2) | CN118955714A (enExample) |
| AU (1) | AU2019231172B2 (enExample) |
| BR (1) | BR112020016049A2 (enExample) |
| CA (1) | CA3090008A1 (enExample) |
| IL (1) | IL276950B1 (enExample) |
| MX (1) | MX2020009366A (enExample) |
| SG (1) | SG11202007199XA (enExample) |
| WO (1) | WO2019173291A1 (enExample) |
| ZA (1) | ZA202004827B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019067425A1 (en) | 2017-09-26 | 2019-04-04 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR TREATING CARDIAC DISEASE BY REDIRECTED T-CELL IMMUNOTHERAPIES |
| MX2020008949A (es) | 2018-02-27 | 2021-01-08 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b. |
| CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| SG11202013216RA (en) | 2018-07-05 | 2021-01-28 | Incyte Corp | Fused pyrazine derivatives as a2a / a2b inhibitors |
| CN112805299B (zh) | 2018-10-05 | 2025-09-16 | 西雅图儿童医院以西雅图儿童研究机构名义经营 | 针对原发性免疫缺陷、胱氨酸病和威尔逊病的新生儿筛查 |
| CN111434688A (zh) * | 2019-01-11 | 2020-07-21 | 上海开拓者生物医药有限公司 | Cd73抗体及其制备方法和应用 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| AU2020353000A1 (en) | 2019-09-23 | 2022-04-07 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (FAP) |
| JP7603670B2 (ja) * | 2019-09-23 | 2024-12-20 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | マウスおよびヒト線維芽細胞活性化タンパク質（ｆａｐ）と交差反応するイヌ線維芽細胞活性化タンパク質に対するモノクローナル抗体 |
| JP7789667B2 (ja) * | 2019-11-15 | 2025-12-22 | ジェンザイム・コーポレーション | 二重パラトープ性ｃｄ７３抗体 |
| US20230042316A1 (en) * | 2019-11-20 | 2023-02-09 | Abvision, Inc. | Monoclonal antibodies that target human cd47 protein |
| IL293868A (en) * | 2019-12-17 | 2022-08-01 | Phanes Therapeutics Inc | Bispecific antibodies with alternatively spliced interchain cysteines and uses thereof |
| WO2021138498A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy |
| AU2020417804A1 (en) * | 2020-01-03 | 2022-07-21 | Incyte Corporation | Anti-CD73 antibodies and uses thereof |
| JP2023519969A (ja) * | 2020-03-31 | 2023-05-15 | シアトル・チルドレンズ・ホスピタル・ドゥーイング／ビジネス／アズ・シアトル・チルドレンズ・リサーチ・インスティテュート | リソソーム蓄積症に関するプロテオミクススクリーニング |
| BR112022021397A2 (pt) * | 2020-04-22 | 2023-02-07 | Akeso Biopharma Inc | Anticorpo anti-cd73, polipeptídeo isolado, molécula de ácido nucleico, vetor, célula hospedeira, conjugado, proteína de fusão ou anticorpo multiespecífico, kit, composição farmacêutica, uso do anticorpo e linhagem celular de hibridoma |
| AU2021261803A1 (en) * | 2020-04-22 | 2023-01-05 | Akeso Biopharma, Inc | Anti-CD73-anti-PD-1 bispecific antibody and use thereof |
| AU2021264006A1 (en) * | 2020-04-30 | 2022-12-01 | Arch Oncology, Inc. | Therapeutic sirpalpha antibodies |
| WO2022037531A1 (zh) * | 2020-08-17 | 2022-02-24 | 中山康方生物医药有限公司 | 抗cd73的抗体及其用途 |
| US20240018254A1 (en) * | 2020-10-23 | 2024-01-18 | Akeso Biopharma, Inc | Anti-cd73 antibody and use thereof |
| CN117285630A (zh) * | 2020-11-09 | 2023-12-26 | 江苏中新医药有限公司 | 抗cd73单克隆抗体及其在制备肿瘤药物中的应用 |
| TWI900705B (zh) * | 2020-12-11 | 2025-10-11 | 大陸商上海華奧泰生物藥業股份有限公司 | Ｃｄ７３的抗原結合蛋白及其應用 |
| US20220233529A1 (en) | 2020-12-29 | 2022-07-28 | Incyte Corporation | Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies |
| CN113061177B (zh) * | 2020-12-31 | 2022-07-01 | 浙江大学 | 一种cd73酶活性相关的抗原表位及针对该表位的特异性抗体的制备方法 |
| US20240174763A1 (en) * | 2021-02-24 | 2024-05-30 | Novoprotein Scientific Inc. | Anti-human cd73 antibody and use thereof |
| GB202105110D0 (en) * | 2021-04-09 | 2021-05-26 | Cancer Research Tech Ltd | Anti-CD73 antibodies |
| AU2022331350A1 (en) * | 2021-08-19 | 2024-03-14 | Adicet Therapeutics, Inc. | Methods for detection of membrane bound glypican-3 |
| CN116265486A (zh) * | 2021-12-17 | 2023-06-20 | 三生国健药业（上海）股份有限公司 | 结合人cd73的抗体、其制备方法和用途 |
| US12187806B2 (en) * | 2022-03-04 | 2025-01-07 | Development Center For Biotechnology | Anti-CD73 antibodies and use thereof |
| CA3256033A1 (en) | 2022-04-13 | 2023-10-19 | Arcus Biosciences, Inc. | POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH-2 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN116063467B (zh) * | 2022-08-24 | 2025-10-14 | 浙江大学医学院附属第一医院 | 抗h10亚型禽流感病毒血凝素蛋白单克隆抗体1f3及其在检测中的应用 |
| WO2024243189A2 (en) * | 2023-05-22 | 2024-11-28 | Board Of Regents, The University Of Texas System | Antigen binding proteins targeting pd-1 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| CN117567632B (zh) * | 2023-11-27 | 2025-10-24 | 福州迈新生物技术开发有限公司 | 抗cd73蛋白单克隆抗体及其制备方法和应用 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2975057A1 (en) | 2006-07-10 | 2016-01-20 | Fujita Health University | Novel anti-cd73 antibody |
| FR3011240A1 (fr) | 2013-10-01 | 2015-04-03 | Centre Nat Rech Scient | Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques |
| WO2015164573A1 (en) | 2014-04-25 | 2015-10-29 | Vitae Pharmaceuticals, Inc. | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| WO2016131950A1 (en) * | 2015-02-20 | 2016-08-25 | Innate Pharma | Cd73 blockade |
| US10766966B2 (en) | 2014-10-10 | 2020-09-08 | Innate Pharma | CD73 blockade |
| HRP20210888T4 (hr) * | 2014-11-10 | 2024-12-06 | Medimmune Limited | Vezujuće molekule specifične za cd73 i njihova upotreba |
| GB2538120A (en) | 2014-11-11 | 2016-11-09 | Medimmune Ltd | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof |
| MX386942B (es) | 2014-11-21 | 2025-03-19 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas. |
| SMT202000413T1 (it) * | 2014-11-21 | 2020-09-10 | Bristol Myers Squibb Co | Anticorpi nei confronti di cd73 e loro usi |
| WO2017064043A1 (en) | 2015-10-12 | 2017-04-20 | Innate Pharma | Cd73 blocking agents |
| EP3387442A4 (en) * | 2015-12-09 | 2019-05-08 | Corvus Pharmaceuticals, Inc. | HUMANIZED ANTI-CD73 ANTIBODIES |
| WO2017118613A1 (en) | 2016-01-08 | 2017-07-13 | Syddansk Universitet | Bispecific antibodies targeting human cd73 |
| KR20230038311A (ko) | 2016-03-04 | 2023-03-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd73 항체와의 조합 요법 |
| EP3481869A4 (en) | 2016-07-11 | 2020-02-26 | Corvus Pharmaceuticals, Inc. | ANTI-CD73 ANTIBODIES |
-
2019
- 2019-03-05 US US15/733,540 patent/US11299550B2/en active Active
- 2019-03-05 KR KR1020257013451A patent/KR20250065424A/ko active Pending
- 2019-03-05 CN CN202411072731.7A patent/CN118955714A/zh active Pending
- 2019-03-05 CN CN201980018305.6A patent/CN111867628B/zh active Active
- 2019-03-05 WO PCT/US2019/020688 patent/WO2019173291A1/en not_active Ceased
- 2019-03-05 MX MX2020009366A patent/MX2020009366A/es unknown
- 2019-03-05 JP JP2020546997A patent/JP7334177B2/ja active Active
- 2019-03-05 AU AU2019231172A patent/AU2019231172B2/en active Active
- 2019-03-05 CA CA3090008A patent/CA3090008A1/en active Pending
- 2019-03-05 SG SG11202007199XA patent/SG11202007199XA/en unknown
- 2019-03-05 KR KR1020207027633A patent/KR102804816B1/ko active Active
- 2019-03-05 BR BR112020016049-0A patent/BR112020016049A2/pt unknown
- 2019-03-05 EP EP19764477.6A patent/EP3762030A4/en active Pending
-
2020
- 2020-08-04 ZA ZA2020/04827A patent/ZA202004827B/en unknown
- 2020-08-26 IL IL276950A patent/IL276950B1/en unknown
-
2023
- 2023-08-14 JP JP2023132024A patent/JP7636483B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019173291A1 (en) | 2019-09-12 |
| AU2019231172A1 (en) | 2020-09-03 |
| CA3090008A1 (en) | 2019-09-12 |
| MX2020009366A (es) | 2020-10-14 |
| NZ766968A (en) | 2024-12-20 |
| JP7636483B2 (ja) | 2025-02-26 |
| ZA202004827B (en) | 2023-06-28 |
| JP7334177B2 (ja) | 2023-08-28 |
| BR112020016049A2 (pt) | 2020-12-08 |
| US20200399389A1 (en) | 2020-12-24 |
| CN111867628A (zh) | 2020-10-30 |
| IL276950B1 (en) | 2025-12-01 |
| AU2019231172B2 (en) | 2023-08-24 |
| EP3762030A4 (en) | 2022-01-05 |
| US11299550B2 (en) | 2022-04-12 |
| KR102804816B1 (ko) | 2025-05-09 |
| CN118955714A (zh) | 2024-11-15 |
| CN111867628B (zh) | 2024-08-23 |
| JP2023162257A (ja) | 2023-11-08 |
| IL276950A (en) | 2020-10-29 |
| KR20200128542A (ko) | 2020-11-13 |
| EP3762030A1 (en) | 2021-01-13 |
| SG11202007199XA (en) | 2020-09-29 |
| JP2021516057A (ja) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102804816B1 (ko) | 항-cd73 항체 및 이의 용도 | |
| KR102784161B1 (ko) | 항-클라우딘 18.2 항체 및 이의 용도 | |
| US12325745B2 (en) | Anti-DLL3 antibodies and uses thereof | |
| US11214615B2 (en) | Anti-TIM-3 antibodies and uses thereof | |
| US11390679B2 (en) | Anti-LAG-3 antibodies and uses thereof | |
| KR102808710B1 (ko) | 항-폴레이트 수용체 1 항체 및 이의 용도 | |
| HK40119299A (zh) | 抗cd73抗体及其用途 | |
| EA043284B1 (ru) | Антитела против cd73 и их применения | |
| HK40031477A (en) | Anti-cd73 antibodies and uses thereof | |
| HK40031477B (zh) | 抗cd73抗体及其用途 | |
| EA046808B1 (ru) | Антитела против dll3 и их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20250423 Application number text: 1020207027633 Filing date: 20200924 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application |